Author:
Brown Karen T.,Chou Joanne F.,Suchy Hannah B.,Getrajdman George I.,Gonen Mithat,Covey Anne M.,Brody Lynn A.,Schattner Mark A.,D’Angelica Michael I.,Kingham T. Peter,Erinjeri Joseph P.,Jarnagin William R.
Abstract
Abstract
Background
To assess the outcome of previously untreated patients with perihilar cholangiocarcinoma who present to a cancer referral center with or without pre-existing trans-papillary biliary drainage.
Methods
Consecutive patients with a diagnosis of perihilar cholangiocarcinoma presenting between January 1, 2013, and December 31, 2017, were identified from a prospective surgical database and by a query of the institutional database. Of 237 patients identified, 106 met inclusion criteria and were reviewed. Clinical information was obtained from the Electronic Medical Record and imaging studies were reviewed in the Picture Archiving and Communication System.
Results
73 of 106 patients (69%) presenting with a new diagnosis of perihilar cholangiocarcinoma underwent trans-papillary biliary drainage (65 endoscopic and 8 percutaneous) prior to presentation at our institution. 8 of the 73 patients with trans-papillary biliary drainage (11%) presented with and 5 developed cholangitis; all 13 (18%) required subsequent intervention; none of the patients without trans-papillary biliary drainage presented with or required drainage for cholangitis (p = 0.008). Requiring drainage for cholangitis was more likely to delay treatment (p = 0.012) and portended a poorer median overall survival (13.6 months, 95%CI [4.08, not reached)] vs. 20.6 months, 95%CI [18.34, 37.51] p = 0.043).
Conclusion
Trans-papillary biliary drainage for perihilar cholangiocarcinoma carries a risk of cholangitis and should be avoided when possible. Clinical and imaging findings of perihilar cholangiocarcinoma should prompt evaluation at a cancer referral center before any intervention. This would mitigate development of cholangitis necessitating additional drainage procedures, delaying treatment and potentially compromising survival.
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma–focus on East and South-Eastern Asia. Asian Pac J cancer Prevention: APJCP. 2010;11(5):1159–66.
2. House MGDAM, Jarnagin WR. Cancer of the bile ducts: extrahepatic biliary tumors. In: Jarnagin WR, editor. Blumgart’s surgery of the liver, biliary tract and pancreas. 1 5th ed. Philadelphia: Elsevier; 2012. pp. 771–88.
3. Lidsky ME, Jarnagin WR. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg. 2018;2(4):304–12.
4. Ellis RJ, Soares KC, Jarnagin WR. Preoperative Management of Perihilar Cholangiocarcinoma. Cancers (Basel). 2022;14(9).
5. Brody LA, Brown KT, Getrajdman GI, Kannegieter LS, Brown AE, Fong Y, et al. Clinical factors associated with positive bile cultures during primary percutaneous biliary drainage. J Vasc Interv Radiol. 1998;9(4):572–8.